HEALTHCARE TRIANGLE INC (HCTI)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-29
$5.14-18.41%
Close 2026-10-30 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-29
Research Workspace
Put HCTI beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — EPS loss narrows toward -$10 by FY27: Comparison needs review.
View ThesisRevenue growth is accelerating — up about 116% over the past year.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 4% on a typical day and fell roughly 100% in its worst 12-month stretch.
View RiskHCTI’s growth-through-acquisitions thesis rests on integrating assets and sustaining expansion. Its six Spain client contracts support that case, but their financial contribution is unspecified. HCTI trades at 0.7× sales versus 1.8× for peers, while expectations look modest versus our view. The model puts the next-quarter miss probability near 52%. The EPS-loss pillar is under pressure, but its FY27 comparison needs review. Peer multiples imply a price about 62% above where it trades. The thesis is on watch, and this read is provisional.
Trailing returns as of 2026-10-30. HCTI is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Continue this research
Compare HCTI with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| HCTI Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Technology — fair value, gap to price, and forward P/E.
Compare the value case
Put HCTI next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Growth through acquisitions and asset integration
Six client contracts support growth and international expansion, though deal value and financial contribution are unspecified.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
